The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Our understanding of the function of the transcriptional regulators YAP and TAZ (YAP/TAZ)
in cancer is advancing. In this Review, we provide an update on recent progress in YAP/TAZ …

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

Eradicating tumor dormancy that develops following epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …

Cancer therapy has traditionally focused on eliminating fast-growing populations of cells.
Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can …